Center-Authored Papers

Filters: Keyword is Antibodies, Monoclonal, Murine-Derived  [Clear All Filters]
B
Buchegger F, Press OW, Delaloye AB, Ketterer N.  2008.  Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.. The oncologist. 13(6):657-67. Abstract
C
Chamberlain MC.  2015.  High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma.. Neurology. 84(7):758-9.
D
Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland ØS, Press OW, Larsen RH.  2007.  Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.. Blood. 110(6):2049-56. Abstract
G
Gopal AK, Pagel JM, Hedin N, Press OW.  2004.  Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.. Blood. 103(9):3516-20. Abstract
Gopal AK, Press OW.  1999.  Clinical applications of anti-CD20 antibodies.. The Journal of laboratory and clinical medicine. 134(5):445-50.
Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT, Garrison MA, Gjerset GF, Lonergan M, Murphy AE et al..  2010.  Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.. Leukemia & lymphoma. 51(8):1523-9. Abstract
Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM.  2008.  Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.. Blood. 112(3):830-5. Abstract
H
Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S et al..  2008.  Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.. Blood. 112(7):2694-702. Abstract
Hensley JL, Sifri CD, Cathro HP, Lobo P, Sawyer RG, Brayman KL, Hackman RC, Pruett TL, Bonatti HJR.  2009.  Adenoviral graft-nephritis: case report and review of the literature.. Transplant international : official journal of the European Society for Organ Transplantation. 22(6):672-7.
L
Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI.  2004.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 22(21):4302-11. Abstract
Lyman GH, Delgado DJ.  2003.  Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.. Cancer. 98(11):2402-9. Abstract
M
Maloney DG.  2008.  What is the role of maintenance rituximab in follicular NHL? Oncology (Williston Park, N.Y.). 22(1):20-6;discussion26,29,33-4. Abstract
Maloney DG.  2012.  Anti-CD20 antibody therapy for B-cell lymphomas.. The New England journal of medicine. 366(21):2008-16.
Maloney DG, Press OW.  1998.  Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.. Oncology (Williston Park, N.Y.). 12(10 Suppl 8):63-76. Abstract
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW et al..  2015.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.. Blood. 125(6):992-8. Abstract
N
Nemecek ER, Green DJ, Fisher DR, Pagel JM, Lin Y, Gopal AK, Durack LD, Rajendran JG, Wilbur SD, Nilsson R et al..  2008.  Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.. Cancer biotherapy & radiopharmaceuticals. 23(2):181-91. Abstract
P
Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.  2005.  Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.. Clinical cancer research : an official journal of the American Association for Cancer Research. 11(13):4857-66. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Press OW.  1999.  Radiolabeled antibody therapy of B-cell lymphomas.. Seminars in oncology. 26(5 Suppl 14):58-65. Abstract
R
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
S
Shan D, Ledbetter JA, Press OW.  2000.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.. Cancer immunology, immunotherapy : CII. 48(12):673-83. Abstract
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
T
Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH, Pagel JM, Holmberg L, Bensinger WI, Press OW.  2008.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.. Leukemia & lymphoma. 49(6):1062-73. Abstract
Z
Zhang MM, Gopal AK.  2008.  Radioimmunotherapy-based conditioning regimens for stem cell transplantation.. Seminars in hematology. 45(2):118-25. Abstract